Status:
TERMINATED
Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes
Lead Sponsor:
Incyte Corporation
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Determine the effect of treatment with INCB019602 administered as an add-on to stable dose metformin therapy in type 2 diabetic subjects on safety and glycemic control.
Eligibility Criteria
Inclusion
- Established diagnosis of T2D
- Currently taking metformin monotherapy at a stable dose level
- FPG between 150 and 270 mg/dL
Exclusion
- History or clinical manifestations of renal impairment
- Hyperglycemia \> 270 mg/dL
- Receiving thiazolidenediones, Exenatide or sulfonylureas within 90 days prior to screening
- Prior use of Acipimox which is known under the name Olbetam within 90 days prior to screening.
- Diagnosed major depression within the last 2 years requiring hospitalization
- History of chronic insulin therapy for glycemic control
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00698789
Start Date
May 1 2008
End Date
June 1 2009
Last Update
October 30 2012
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85029
2
Tucson, Arizona, United States, 85705
3
Chula Vista, California, United States, 91911
4
Los Angeles, California, United States